Wendy K.D. Selig, President
Donald L. Trump, MD, FACP, Treasurer
Carolyn R. Aldigé, Secretary


Robert R. Clark, M.S., FACHE
Stephen S. Grubbs, MD
Lisa Hughes
Anne L. Levine, M.Ed, MBA
Elizabeth B. O’Brien
David Pugach, J.D.
Jon Retzlaff, M.P.A., M.B.A.
Richard L. Schilsky, MD
Ellen V. Sigal, PhD
Barbara Duffy Stewart, MPH, Past President
Frank M. Torti, MD, MPH, FACP

Sustaining Directors

Maguerite Donoghue Baxter, RN, MN
Margaret Foti, PhD, MD (h.c.), Past President
Philip J. Stella, M.D.

In Memoriam

Donald S. Coffey, PhD
Robert L. Comis, MD, Treasurer


Wendy K.D. Selig, President
Founder and CEO, WSCollaborative

Wendy K.D. Selig is Founder and CEO of WSCollaborative, a firm that focuses on defining and implementing strategies for establishing winning cross-sector collaborations in the health care arena.

From 2009-2015, Selig served as President and CEO of the Melanoma Research Alliance (MRA), where she led and managed MRA’s strategic priorities, research portfolio, engagement with more than 90 corporate and non-profit Allies, and day-to-day operations.

Selig has held leadership roles in numerous coalitions, including serving as founding President of United for Medical Research (UMR) and chair of One Voice Against Cancer (OVAC). She has served on the National Cancer Institute (NCI) Director’s Consumer Liaison Group (DCLG). She has served on the Patient Leadership Council of the Clinical Trials Transformation Initiative (CTTI) and the Government Affairs Committee of the Prostate Cancer Foundation (PCF), as well as the National Comprehensive Cancer Network’s (NCCN) Tissue Allocation Subcommittee.

Prior to joining the MRA, Selig spent nearly a decade in leadership positions at the American Cancer Society (the Society) and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN). At ACS CAN, she served as Vice President of External Affairs & Strategic Alliances, Managing Director, Federal Government Relations and Vice President for Legislative Affairs. From 1989-2000, Selig served on Capitol Hill as a senior staff member for U.S. Representative Porter J. Goss (R-FL), the House Rules Committee and the House Permanent Select Committee on Intelligence (HPSCI).
A native of Princeton, NJ, Selig is a Magna Cum Laude graduate of Princeton University and holds a Masters in Science (With Distinction) from Northwestern University’s Medill School of Journalism. She and her husband Michael live with their two children in McLean, VA.

Donald L. Trump, MD, FACP
President and CEO
Roswell Park Cancer Institute

Dr. Donald L. Trump was appointed President and Chief Executive Officer of Roswell Park Cancer Institute (RPCI) on April 1, 2007. On first coming to RPCI in January 2002, Dr. Trump served as Senior Vice President for Clinical Research; Chair, Department of Medicine; and Co-Principal Investigator (PI) of the Cancer Center Support Grant (CCSG) funded by the National Cancer Institute. He was appointed Associate Institute Director in the fall of 2006 and became President and CEO of RPCI, and PI of the CCSG, in 2007.

Dr. Trump has direct authority over day-to-day operations, philanthropic and operating budgets, capital improvements, research priorities and clinical and scientific strategic planning for the Institute. He is responsible for establishing a culture of excellence throughout RPCI’s key mission areas: research, clinical care, education and cancer prevention.

In addition to his role as President and CEO, Dr. Trump continues his work as a clinical scientist and physician. He leads the Institute’s strong clinical research program in vitamin D-based cancer prevention and treatment, and he cares for patients with prostate cancer and other urologic cancers. He is principal investigator or co-principal investigator on several grants funded by the National Cancer Institute. He holds European and U.S. patents for the use of vitamin D and vitamin D analogs in combination with high-dose chemotherapy.

Dr. Trump earned his medical degree from The Johns Hopkins University School of Medicine, Baltimore, MD, in 1970. From 1970 to 1975, he completed an internship and residency training in Medicine and a fellowship in Oncology and served as Chief Resident in Internal Medicine at The Johns Hopkins Hospital. Dr. Trump is a Diplomate of the American Board of Internal Medicine, with Subspecialty Boards in Medical Oncology, and a Fellow of the American College of Physicians.

Carolyn R. Aldigé, Secretary & Past President
Founder and President
Prevent Cancer Foundation

Carolyn R. (“Bo”) Aldigé is the Secretary National Coalition for Cancer Research. She has served on the Board of Directors since 1996 and was president from 1998-2004.

Ms Aldigé founded the Prevent Cancer Foundation in 1985 in memory of her father, Edward P. Richardson, who died of cancer one year earlier. In the 25 years since its inception, the Prevent Cancer Foundation has provided more than $120 million in support of its mission: cancer prevention and early detection through research, education, community-based programs and advocacy, and has become nationally recognized as a leader in the fight against cancer through prevention.

She also serves on boards of directors/advisors of six National Cancer Institute-designated Cancer Centers and as a member of the board of four additional non-profit cancer-related organizations. She has been a member of C- Change (formerly the National Dialogue on Cancer) since its inception.

She serves on several key committees of this organization, as well as committees and task forces of the American Association for Cancer Research, the American Society of Clinical Oncology, the American Society of Preventive Oncology and the Coalition for a Stronger FDA. She is vice-president of the Global Lung Cancer Coalition and a member of the steering committees of the International Digestive Cancer Alliance and National Colorectal Cancer Roundtable.

For her many contributions to the Washington, DC community, Carolyn Aldigé was named Washingtonian of the Year in 1996. She is the only individual who has received Public Service Awards from the American Association for Cancer Research, the American Society of Clinical Oncology and the American Society of Preventive Oncology.

She has been honored by numerous non-profit organizations and cancer centers, as well as the National Cancer Institute. She has been invited to speak on numerous occasions to lay and professional audiences, both nationally and internationally.



Robert R. Clark, M.S., FACHE

Rob Clark has held progressively responsible positions in health care management since completing a Master’s of Science in Health Care Administration in 1986 from the University of Mississippi. He has been responsible for the operations of acute and long term care facilities with multi-million dollar budgets and has been directly accountable for over 200 employees. He was employed by Baptist Memorial Health Care Corporation in Memphis prior to joining St. Jude Children’s Research Hospital in 2002.

In his current role at St. Jude as Director of Government Affairs, Mr. Clark is responsible for public policy and external affairs for the institution at the federal, state and local levels. He also serves as liaison for the Cancer Center for State and Federal Outreach. He served on the Executive Committee of the TN Cancer Coalition from 2009-2012.

Mr. Clark is a graduate of Leadership Memphis and Leadership DeSoto and has been a leader in the Mid-South through work in many non-profit organizations including the YMCA, Rotary International, Big Brothers/Big Sisters, Evergreen Historic District Association, Grace-St. Luke’s Episcopal Church, DeSoto Health and Wellness Center, University of Memphis School of Public Policy, Coalition for a Better Memphis and Family Services of the Mid-South.
His special community interests include health care for the underserved cancer population and control, regional economic development, and politics.

Louis J. DeGennaro, Ph.D.
Executive Vice President and Chief Mission Officer

Leukemia and Lymphoma Society

As Chief Mission Officer of the Leukemia and Lymphoma Society, Dr. DeGennaro’s responsibilities include oversight of all LLS mission functions: Public Policy, Patient Services and Research with the goal of effectively deploying resources in pursuit of the LLS mission.

Dr. DeGennaro has more than 25 years of research, drug development and executive management experience in academic and private-sector settings. He received his Ph.D. in biochemistry from the University of California at San Francisco and did his postdoctoral research at Yale University School of Medicine. His previous academic appointments include research group leader at Max Planck Institute in Munich, Germany, and associate professor of neurology and cell biology at the University of Massachusetts Medical School.
Dr. DeGennaro’s private-sector positions include senior director of molecular genetics at Wyeth Pharmaceuticals, Princeton, NJ, and executive vice president for research and development, SynX Pharma, Inc., Toronto, Canada.

Lisa Hughes
Senior Director, Policy and Advocacy
Prevent Cancer Foundation

Lisa Hughes joined the National Patient Advocate Foundation staff on August 4,2014 as Director of Strategic Partnerships and Projects. In this role, she leads a coalition of organizations with a shared interest in defining opportunities and challenges in innovation within oncology. In this capacity, she directs the dual focuses of the coalition – building public demand and knowledge through education and direct patient services, and spearheading the coalition’s advocacy effort to impact policy.

Prior to joining NPAF. Lisa held the position of Director, Patient Advocacy Relations for Allergan, Inc., leading Allergan’s strategic alliances with the patient advocacy in Urology and Neuroscience and managing corporate sponsorships and contributions.

From October 1998-March 2013, Lisa served in various positions at the Prevent Cancer Foundation, including Senior Director, Policy and Advocacy and Managing Director of External Affairs. As a member of the Foundation’s leadership team, she led government affairs, grassroots advocacy, policy development, corporate partnerships and communications initiatives. Lisa served as Foundation representative to multiple health policy coalitions, and in coalition leadership as a member of the Board of Directors of the National Coalition for Cancer Research and in the roles of President and Vice President of Membership and Board Member of the Coalition for the Advancement of Medical Research (CAMR.)

Prior to joining the Prevent Cancer Foundation staff, Lisa was employed by two, Members of Congress from the state of New Jersey from 1991 through 1998.

She is a graduate of Rhodes College in Memphis, TN and resides outside of Philadelphia, PA with her husband and two children.

Anne L. Levine, M.Ed, MBA

Anne Levine is the Vice President of External Affairs at Dana-Farber Cancer Institute. In her current role, she is responsible for government relations on the state and federal level, legislative advocacy in partnership with Dana-Farber patients and families, and community outreach programs designed to reduce the cancer burden among medically underserved populations. She has been actively involved in advocacy regarding state and federal health reform, with the goal of ensuring access and removing financial barriers for patients seeking high-quality cancer care and access to clinical trials.

Prior to joining Dana-Farber in 1995, she had worked at other academic medical centers in Boston including Tufts Medical Center as Director of Planning (1985-1992) and Administrative Director of the Proton Therapy Center at Massachusetts General Hospital (1992-1995).

Ms. Levine serves on the steering committee for the Massachusetts Comprehensive Cancer Control Program and serves on numerous government relations committees including the Association of American Cancer Institutes, Alliance of Dedicated Cancer Centers, American Cancer Society, Massachusetts Hospital Association and Conference of Boston Teaching Hospitals (COBTH). She is past chair of the COBTH community benefits committee.

She has been an author on several community health improvement papers including: an evaluation of patient navigators programs in a cancer center setting; evaluation of a mobile mammography program serving low-income and underserved women; and an article on the approach used to launch a cancer clinic based at a federally qualified health center.

Ms. Levine serves on the Board and Chairs the Governance Committee at Fenway High School, a pilot school in the City of Boston. She also serves on the Board of the Mass. Taxpayers Association.

Ms. Levine earned a master’s degree in counseling psychology and an MBA in health care management from Boston University, and a BA degree in psychology from Washington University in St. Louis.

David Pugach, J.D.

David Pugach is Director of Federal Relations for the American Cancer Society Cancer Action Network. Prior to joining ACS CAN, Mr. Pugach served as the Deputy Director of the National Cancer Institute Office of Government and Congressional Relations. From February 2006 to February 2007, he was detailed to the House Committee on Appropriations. Mr. Pugach joined NCI in the summer of 2003 after serving for two years as a Presidential Management Fellow with the National Institutes of Health.

Mr. Pugach leads ACS CAN’s efforts to promote federal funding for cancer research and prevention programs. This includes direct lobbying of Congress throughout the federal budget process. Additionally, he serves as Executive Director of One Voice Against Cancer, a coalition of over 40 cancer organizations that advocates for increased funding for federal cancer programs.

Mr. Pugach has a B.A. in political science from The George Washington University and a J.D. from the Rutgers University School of Law.

Jon Retzlaff, M.P.A., M.B.A.

Before joining the AACR in 2010 as the managing director of science policy and government affairs, Mr. Retzlaff led the health and biomedical practice for a government relations firm in D.C. Prior to these two positions, he served as legislative director for the Federation of American Societies for Experimental Biology from 2004-2007.

Additionally, he worked for the National Institutes of Health, first as a program analyst within the Office of the Director’s legislative office; then as a senior legislative advisor to the National Institute of Neurological Disorders and Stroke; and finally as the executive officer of the National Library of Medicine. Mr. Retzlaff was assigned to the House (1998) and Senate (2000-2001) appropriations subcommittees on labor, health and human services, education and related agencies on health research funding issues, as well as within the Office of the Secretary for Legislation at the Department of Health and Human Services. He entered the Federal Government as a Presidential Management Intern in 1993 and completed a rotation in the Office of Senator Herb Kohl (D-Wis.) during his training.

Mr. Retzlaff earned a Bachelor of Science degree from the University of Minnesota, a master’s degree in public administration from Indiana University and a master’s degree in business administration from the Massachusetts Institute of Technology.


Richard L. Schilsky, MD
Professor of Medicine and Section Chief of Hematology and Oncology
University of Chicago

Dr. Schilsky, a medical oncologist, is Professor of Medicine at the University of Chicago. Since 1995, he has served as Chair of Cancer and Leukemia Group B, presiding over a national research network that conducts clinical trials in cancer treatment, biology, prevention and health outcomes. Dr. Schilsky’s research focus is gastrointestinal cancers and cancer pharmacology and drug development, and his research has been continuously funded by the National Cancer Institute (NCI) since 1987.

Dr. Schilsky is the past President of the American Society of Clinical Oncology. Having served since served on the Board of Directors from 2002–2005. Dr. Schilsky is an active member of American Association for Cancer Research, the European Society for Medical Oncology, the American Society
for Clinical Pharmacology and Therapeutics, the American College of Physicians, the American Association for Cancer Education, the International Society of Geriatric Oncology, the Association for Patient-oriented Research, and the Society for Clinical Trials. He has been a member of the NCI Board of Scientific Advisors since 1999, was appointed to the Clinical Trials Advisory Committee, and has served on numerous peer review and advisory committees. He has also been a member and chair of the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration.

Dr. Schilsky is an associate editor of Clinical Cancer Research and on the Editorial Board of Molecular Oncology, Seminars in Oncology, the Journal of Cancer Research and Clinical Oncology, Clinical Advances in Hematology & Oncology, The Oncologist, and CURE. He has published more than 250 articles and manuscript chapters and is the editor of four books.

Dr. Schilsky earned a medical degree with honors from the University of Chicago Pritzker School of Medicine. Following a residency in internal medicine at the University of Texas Southwestern Medical Center and Parkland Memorial Hospital, he received training in medical oncology and clinical pharmacology at the NCI.

Wendy K.D. Selig
President and Chief Executive Office
Melanoma Research Alliance

Wendy K.D. Selig is president and CEO of the Melanoma Research Alliance (MRA), a public charity focused on finding and funding the most promising melanoma research worldwide that will accelerate progress toward a cure. Selig drives and manages MRA’s strategic priorities, research portfolio, and day-to-day operations. Under her leadership, the MRA is accelerating progress toward a cure for melanoma by supporting an international, cross-disciplinary group of biomedical researchers exploring, identifying, and pursuing innovative, transformative research. Founded by Debra and Leon Black in 2007 and established under the auspices of the Milken Institute, MRA has provided millions of dollars for cutting-edge research in the areas of melanoma prevention, diagnosis, and treatment.

Prior to joining the MRA, Selig spent nearly a decade in leadership positions at the American Cancer Society (the Society) and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN). Most recently, she served as ACS CAN’s vice president of external affairs & strategic alliances, where she built strategic partnerships with corporations, foundations, trade associations, and federal agencies. She oversaw the Society’s campaign to ensure access to quality healthcare and chaired United for Medical Research a coalition of patient advocacy groups, universities, and business interests focused on sustained federal support for biomedical research funding at the NIH. She also provided leadership for One Voice Against Cancer, a coalition of more than 40 groups collaborating to secure enhanced federal funding for cancer programs. In 2008, Selig was appointed to serve on the National Cancer Institute Director’s Consumer Liaison Group.

Selig’s work with the Society and ACS CAN began in 2000, when she served first as managing director, federal government relations and later vice president for legislative affairs. From 1989-2000, Selig served on Capitol Hill as a top aide for U.S. Representative Porter J. Goss (R-FL), the House Rules Committee, and the House Permanent Select Committee on Intelligence.

A native of Princeton, NJ, Selig is a magna cum laude graduate of Princeton University and holds a Master in Science (with distinction) from Northwestern University’s Medill School of Journalism.

Ellen V. Sigal, PhD
Chairperson and Founder
Friends of Cancer Research

Ellen V. Sigal, PhD, is Chairperson and Founder of Friends of Cancer Research (“Friends”), a cancer research think tank and advocacy organization based in the Washington, DC metropolitan area. Friends is dedicated to accelerating the nation’s progress toward prevention and treatment of cancer by mobilizing public support for cancer research funding and providing education on key public policy issues. For more than 14 years, Friends has pioneered innovative public‐private partnerships, organized critical policy forums, educated the public and brought together key communities to develop collaborative strategies in the field of cancer research.

Dr. Sigal is Vice Chair of the inaugural board of directors of the Reagan‐Udall Foundation, a partnership designed to modernize medical product development, accelerate innovation, and enhance product safety in collaboration with the U.S. Food and Drug Administration. She serves on the National Institutes of Health Foundation Board chairing its Public‐Private Partnerships Committee, the American Association for Cancer Research Foundation Board, and the Research!America Board. Dr. Sigal is a member of the Stand Up To Cancer (SU2C) Advocate Advisory Council, and she is one of two Council members nominated to the SU2C Scientific Advisory Committee.

She holds leadership positions with a broad range of cancer advocacy and public policy organizations, and leadership positions with academic health centers including the M. D. Anderson Cancer Center External Advisory Board, the Duke University Cancer Center Board of Overseers, and The Sidney Kimmel Comprehensive Cancer Center Advisory Council. She serves on the C‐Change Research Committee and the Entertainment Industry Foundation Oversight Committee for the Biomarker Discovery Project. Dr. Sigal was recently named to the Patient Centered Outcomes Research Institute (PCORI) Board of Governors as a representative of patients and health consumers.

During her more than twenty year commitment to cancer research, Dr. Sigal has served in a number of critical public positions. She served on the National Cancer Institute Board of Scientific Advisors from 2003‐2009, and the National Institutes of Health Director’s Council of Public Representatives from 2003−2006. She was a Presidential Appointee to the National Cancer Advisory Board from 1992‐1998, where she chaired the Budget and Planning Committee that oversees the federal cancer budget. In 1998, Dr. Sigal was named Vice Chairman of the Board of The March, a national grassroots advocacy group that brought thousands of volunteers to Washington to liaise with Congress and to set a new advocacy agenda for cancer research and treatment. She is a past member of the American Society of Clinical Oncology Foundation Board. Dr. Sigal has also been instrumental in harnessing the energies of Hollywood on behalf of cancer research, serving as President of The Creative Community Task Force for Cancer Research.

Barbara Duffy Stewart, MPH
Executive Director
Association of American Cancer Institutes

Barbara Duffy Stewart is President of the National Coalition for Cancer Research.  She has been a member of the Board of Directors since 2000, and served as President-Elect from 2010-2012.

Ms. Stewart has served as executive director of the Association of American Cancer Institutes (AACI), comprising 95 of the leading academic and free-standing cancer research centers in the United States since 1999. Ms. Stewart oversees all administrative, financial and external affairs of the Association, and conceives and implements programs and strategies that benefit the nation’s cancer centers and contribute to the goals of the national cancer program.

Before joining AACI, Ms. Stewart was director of Communications and Public Affairs at the University of Pittsburgh Cancer Institute (UPCI). She was responsible for UPCI’s interactions with business, community, and government leaders to increase awareness of UPCI’s novel cancer programs and activities.

Ms. Stewart also managed government affairs for UPCI. She was instrumental in the founding of the Pennsylvania Cancer Alliance, an association of Pennsylvania cancer centers that secured 19 percent of Pennsylvania’s tobacco settlement funds for biomedical research.

Ms. Stewart serves on the executive committee of Friends of Cancer Research, Washington, DC, and is a member of the Metro board of directors of the YMCA, Pittsburgh. She previously served on the board of directors of the Education Network to Advance Cancer Clinical Trials (ENACCT), the Center for Victims of Violent Crime, and Family House, Inc., where she was a member of the executive committee and chaired the public relations committee.

Ms. Stewart earned a Master of Public Health degree at the University of Pittsburgh and a Bachelor of Arts degree in American Government at Georgetown University.


Frank M. Torti, MD, MPH, FACP
Vice President of Strategic Programs
Wake Forest University
Past Acting Commissioner, US Food and Drug Administration

Dr. Torti received his B.A. and M.A. degrees from Johns Hopkins University, his M.D. from Harvard Medical School (cum laude), and his M.P.H. from the Harvard School of Public Health, where he trained in cancer epidemiology and nutrition. He was an intern and resident at the Beth Israel Hospital, Boston, a Harvard teaching hospital, and a fellow in medical oncology at Stanford University. While on the Stanford faculty, he served as Executive Officer of the Northern California Oncology Group and Associate Director of the Northern California Cancer Program, and was instrumental in the development and oversight of the data management functions and overall administration of that NCI-designated clinical cooperative group and its regional network in northern California. While at Stanford, he led one of the most active genitourinary programs in the country. He was tenured at Stanford University.

Dr. Torti joined Wake Forest University School of Medicine in 1993 as the Charles L. Spurr Professor of Medicine, Director of the Comprehensive Cancer Center, and Chair of the Department of Cancer Biology. He developed and is principal investigator on a training program in cancer biology for PhD students and MD and PhD postdoctoral fellows that is funded by an NIH T32 grant. He is the founding and past president of the Cancer Biology Training Consortium, a national society of cancer biology chairs and program directors that now involves 70 US academic medical centers.

He has published in Science, J. Biol. Chem., Mol. Cell. Biol., Proc. Nat. Acad. of Sci., J. Immunol., J. Clin. Oncol., Lancet, Cancer Res., New Eng. Jour. Med., Ann. Int. Med., Cell, and other highly respected journals. He has served on or chaired a number of national study sections, including those of the NIH, VA, DOD, and American Institute for Cancer Research. He currently is a member of the External Advisory Boards of four Comprehensive Cancer Centers, as well as the nominating committee for the American Association of Cancer Institutes. He served on the NIH Council for the National Center for Complementary and Alternative Medicine, and was recently appointed to the NCI’s Board of Scientific Advisors.

Dr. Torti is an active and well known clinical investigator in urologic oncology. He is widely published in this area and has designed and executed clinical trials that have become standards of care in genitourinary oncology. He has routinely been selected by his peers for lists in national magazines of “America’s top doctors” and “top cancer doctors.”

Dr. Torti has made fundamental observations on the molecular action of oxidants and cytokines and their relationship to cancer and iron homeostasis. His recent interests include alterations in iron homeostasis in cancer and the development of novel antiangiogenic compounds. He has been continually funded by an NIH RO1 grant for his basic science research since his lab was established in 1988. He holds a MERIT award from the NIH, an honor bestowed on only 3% of all NIH grantees.

In 2008, Dr. Torti took a leave from Wake Forest to accept an appointment as the U.S. Food and Drug Administration’s Principal Deputy Commissioner (second ranking official) and the FDA’s first Chief Scientist, a new position mandated in the FDA Amendments Act of 2007. As Chief Scientist, a number of FDA offices and centers reported directly to him, including the Office of Critical Path Programs, the National Center for Toxicological Research, the Offices of Fellowship and Training, Genomics and Personalized Medicine, Pediatric Therapeutics, Special Health Issues, Orphan Drugs, Women’s Health and Combination Products. While Chief Scientist, Dr. Torti developed and implemented the FDA commissioner’s fellowship program, established a new FDA Journal of Regulatory Science, developed the overarching vision and priorities and implementation plan for FDA science, created a plan for recruitment, retention and career development in the Office of Oncology Drug Products (for which he received a Department of Health and Human Services “Commissioner’s Commendation”), established the first FDA science writers symposium, developed a program of peer-reviewed “science first” research awards, developed an HHS-wide economic adulteration task force, and coordinated the scientific integration of the FDA’s informatics transformation.

In January 2009, Dr. Torti was appointed Acting Commissioner of the FDA. He managed complex multi-state food-borne illness outbreaks, and initiated a scientific taskforce on scientific tools for rapid detection of pathogens that coordinated efforts of the Department of Homeland Security, DARPA, CDC, FDA, USDA, NIST, and NIH. He also developed strong collaborations with NIH and NCI leadership to tackle complex scientific issues surrounding rodent and primate toxicology and human epidemiology of estrogen disruptors. Dr. Torti was able to develop at the FDA a strong and growing sense of community around the preeminence of science in a regulatory agency.

Dr. Torti returned to Wake Forest in the spring of 2009 to assume the newly created position of Vice President for Strategic Programs as well as resuming his positions as Director of the Comprehensive Cancer Center and Chair of the Department of Cancer Biology. As part of the new position, Dr. Torti leads and provides oversight for not only the scientific, but also financial and strategic initiatives of all inpatient and outpatient cancer clinical programs.

Stephen S. Grubbs, MD

Dr. Grubbs has been for the past thirty years a private practicing Medical Oncologist in Newark, Delaware at the Helen F. Graham Cancer Center. He is a chemical engineering graduate of Purdue University and graduate of the
Thomas Jefferson University Medical School. Medical postgraduate training in Internal Medicine was completed at the Medical Center of Delaware and Hematology and Oncology at the Dartmouth Hitchcock Medical Center.

He serves as Principal Investigator of the Delaware Christiana Care NCORP, Board member of the Alliance cooperative research group, and State of Delaware Cancer Consortium Council member and Early Detection and Prevention Committee Chair. He also serves on the American Society of Clinical Oncology (ASCO) Board of Directors, Ethics Committee, Finance
Committee, and Exemplary Clinical Trials Site Subcommittee. He is a past member of the ASCO Research and Government Affairs Committees.

He is a Clinical Assistant Professor of Medicine of the Thomas Jefferson Medical School faculty. Dr. Grubbs has served as a member of the National Cancer Institute Clinical Trials Advisory Committee, co-chair of the Clinical Trials Subcommittee of the NCI Community Cancer Centers Program (NCCCP), and the IOM Committee on Cancer Clinical Trials and the NCI Cooperative Group Program.

He has been an active community based clinical trial investigator with CALGB, ECOG, NSABP, and Alliance Cooperative Groups since 1984 and is the recipient of the 2007 Association of Community Cancer Centers David King Community Clinical Scientist Award. His practice, Medical Oncology Hematology Consultants, P.A., is honored as a recipient of the 2008 ASCO Clinical Trials Participation Award, is QOPI certified, and is one of the vanguard ASCO CancerLinQ practices.

Elizabeth B. O’Brien

Elizabeth Brooks O’Brien is Vice President, Legal and External Affairs as well as General Counsel of the The Wistar Institute in Philadelphia, Pennsylvania. In this capacity, Ms. O’Brien oversees legal affairs, providing counsel on corporate governance, regulatory compliance, intellectual property and technology transfer, contracting (including design/construction agreements), immigration, museum/archival holdings, academic affairs and employment law. She also manages government affairs activities at local , state and federal level. Co-founder of the Pennsylvania Cancer Alliance, a coalition of the Commonwealth’s leading cancer research centers that advocates for research funding.

Prior to joining The Wistar Institute, Ms. O’Brien served as Associate General Counsel of the University of Pennsylvania. She provided counsel to the University on a broad range of legal issues, including research and intellectual property, real estate, employment discrimination and general contract matters. Individual clients included the University’s Nursing School, the Morris Arboretum of the University of Pennsylvania and WXPN, the University’s radio station.

Ms. O’Brien serves on the Government Affairs Committee of the Association of American Cancer Institutes; Co-Founder and Coordinator of the Pennsylvania Cancer Alliance; Past Chair of the Board of Directors, Philadelphia Corporation for Aging and is a member of the Association of Independent Research Institutes.

She received her Bachelor of Arts Degree from Bryn Mawr College and her Juris Doctor Degree from the University of Pennsylvania Law School.


Maguerite Donoghue Baxter, RN, MN
Senior Vice President

Trained as an oncology clinical nurse specialist, Ms. Baxter joined the National Institutes of Health’s (NIH) National Cancer Institute (NCI) to guide the clinical nursing care for patients participating in clinical trials. Having worked in political campaigns, she transitioned into an NIH AIDS policy coordination role which eventually led to a 22 year career in government affairs and public policy in the private sector.

Ms. Baxter has represented numerous biopharmaceutical companies, nonprofit patient organizations, foundations and academic medical research institutions, such as the Johns Hopkins University, Fred Hutchinson Cancer Research Center and Columbia University. For the past 11 years she has worked on global public policy and government affairs issues in the C-Suite of two Fortune 100 companies and a global biotech company. Ms. Baxter’s leadership experience in Novartis Vaccines and Diagnostics, Inc., Chiron Corporation and Pharmacia Corporation (Pfizer) has enabled her to be at the forefront of policy opportunities in biopharmaceutical innovation in the evolving global health care systems.

Margaret Foti, PhD, MD (h.c.), Past President
Chief Executive Officer
American Association for Cancer Research

A native of Philadelphia, Margaret Foti, Ph.D., M.D. (h.c.), earned a master’s degree and doctorate in communications from Temple University in Philadelphia. Foti’s graduate education and training focused on scientific communications, especially communications research, scientific publishing and information science. At the AACR, Foti progressed through several key management roles in scientific publishing to become chief executive officer in 1982. Working collaboratively with the elected officers of the AACR, she has provided the corporate knowledge and continuity of leadership that has been critical to the association’s progress and its mission to prevent and cure cancer. During Foti’s tenure, the AACR’s membership has grown from about 3,000 to 32,000 basic, translational and clinical researchers, health care professionals, students, cancer survivors and advocates in the United States and more than 90 other countries.

Foti joined the AACR as an editorial assistant for Cancer Research (the most highly cited cancer journal in the world) under the editorship of her first mentor Michael B. Shimkin, M.D. She was rapidly promoted to the position of managing editor under the editorship of Sidney Weinhouse, Ph.D., and became the youngest managing editor of a major scientific journal in the country. Foti has launched six additional major peer-reviewed journals: Cancer Discovery, Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. These publications contribute more than 26,000 scientific pages to the cancer literature every year. In 2006, the AACR launched CR, a magazine for cancer survivors, their families, patient advocates, physicians and scientists.

Most recently, Foti has led the AACR’s scientific partnership of Stand Up To Cancer, a charitable initiative that supports groundbreaking research aimed at getting new cancer treatments to patients in an accelerated time frame. The AACR plays an integral role by providing scientific leadership, expert peer review and grants administration and oversight.

Among her many professional activities, Foti serves as a board member of and is a past-president of the National Coalition for Cancer Research. She is also a member of the Melanoma International Foundation scientific advisory board; a member of the executive committee and board of Friends of Cancer Research; a board member of the Greater Philadelphia Chamber of Commerce and its Life Sciences Congress; a medical advisory board member of the Prevent Cancer Foundation; and a council member of the Council of the European Association for Cancer Research. She is a member of the Wellness Leadership Council; a strategic advisory panel member of the International Union Against Cancer; a scientific advisory board member of the King Hussein Biotechnology and Cancer Institute; a member of the 2009 National Advisory Committee for the Review of Cancer and National Health Reform Legislation at George Washington University Medical Center; and an external advisory board member for the University of Michigan Institute for Clinical and Health Research and National Institutes of Health Clinical and Translational Science Award Program.

Foti previously served as a board member of the Translational Genomics Research Institute (TGen). She was also a board member and president of the Council of Science Editors and the Society for Scholarly Publishing. She has served in various capacities for the International Federation of Science Editors, the General Motors Cancer Research Foundation, the European Life Science Editors Association, the American Cancer Society and the American Heart Association, among other organizations. Foti has also been a consultant to several nonprofit organizations and lectures widely at academic institutions in the United States and abroad.

Foti has received many national and international awards for her contributions to cancer research. In 2009, she won the first Margaret Kripke Legend Award from the University of Texas M. D. Anderson Cancer Center, the European CanCer Organization Lifetime Achievement Award, and received a citation from Philadelphia Mayor Michael Nutter for her dedication to increasing awareness of the importance of cancer research as well as her pivotal role in creating National Cancer Research Month in May. She was the first recipient of an AACR award created in her name in 2007. Additionally, Foti has won the Award of Appreciation from the Frontiers in Cancer Prevention Research Chairpersons, the Award with Recognition and Appreciation from the Israel Cancer Association, the Italian League Against Cancer Commendation, the Distinguished Service Award from the George Washington University Medical Center’s GW Cancer Institute, the Distinguished Service Award from the Association of American Cancer Institutes, the AACR Award for Leadership and Extraordinary Achievements in Cancer Research, the Ville de Paris Award, the Cina del Duca Award for raising public awareness of cancer globally, the Community Caring Award from the William S. Graham Foundation for Melanoma Research and the Special Recognition Award from the American Society of Clinical Oncology for her work in advancing clinical cancer research.

For her work, Foti has also been awarded honorary memberships in the Japanese Cancer Association, the European Association for Cancer Research and the Hungarian Cancer Society. She was awarded an honorary doctorate in medicine and surgery from the University of Rome La Sapienza in 2003. She received a second honorary doctorate in medicine and surgery from the University of Catania in Sicily in July 2008 and a third honorary doctorate in medicine from the University of San Pablo CEU in June 2009.

Philip J. Stella, M.D.
Medical Director
St. Joseph Mercy Hospital Cancer Center

As a founding member and Past President of the Michigan Society Hematology and Oncology Phil Stella has dedicated much of his time and talent to the advancement of cancer care in Michigan. In addition to being a medical oncologist in private practice, he is also Medical Director of the St. Joseph Mercy Hospital Cancer Center, Principal Investigator of the Michigan Cancer Research Consortium CCOP and Principal Investigator of NCI National Community Cancer Centers Program (NCCCP). Dr. Stella’s academic appointments include Adjunct Associate Professor of Medicine at the University of Michigan Medical Center where he was Research Director of the University of Michigan Cancer Center Regional Network.

Receiving a Bachelor of Science Degree from the University of Michigan in 1973 and a Medical Degree from Michigan State University in 1978, Dr. Stella completed his internship and residency in Internal Medicine at St. Joseph Mercy Hospital in Ann Arbor MI (1978-1981). He subsequently did a fellowship in Medical Oncology at Mayo Clinic (1982-1984).

Dr. Stella has been very involved with promoting clinical trials not only through the Michigan Cancer Research Consortium CCOP but also as co-chair of the Clinical Trials Work Group for the Michigan Cancer Consortium, a Michigan Department of Public Health sponsored, statewide network of organizations providing leadership and coordination to achieve priority cancer control objectives for the state. In his role as convener of the Michigan Working Group to Improve Cancer Outcomes, Dr. Stella initiated and facilitated discussions with Blue/Cross Blue Shield, the Michigan Association of Health Plans, Michigan’s major employers, cancer patient advocacy groups and cancer clinical research providers. As chairman of this coalition, he successfully guided this task force to reach consensus on agreement ensuring coverage of the routine healthcare costs associated with patients enrolled in Phase II and III clinical trials in the state of Michigan. He continues to work with these same organizations and ASCO, ACCC and the Coalition of National Cancer Cooperative Groups to promote a standard oncology benefits package, including coverage for Phase I trials, cancer prevention and screening activities, hospice benefits and oral drug coverage. He currently is working with Blue Cross Blue Shield of Michigan (BCBSM) on a number of payor initiatives through the Pathways Program and Quality Oncology Practice Initiatives (QOPI). He is a Board Member of Alliance for Clinical Trials in Oncology and on the Alliance Executive Committee.

In the national arena, Dr. Stella served on the American Society of Clinical Oncology’s Board of Directors from 1999 – 2002. The last two years of his board term, he held a position on ASCO’s Finance Committee helping evaluate and select a new investment manager for ASCO’s blind trust. During his Board tenure, Dr. Stella was involved in developing ASCO’s strategic plan and co-chaired the Task Force on Quality. His other ASCO related activities include Clinical Practice Committee (1996-1999), Health Services Research Committee (1998-2002), Board Liaison to the CME Committee (2000 – 2001), Cancer Prevention Committee (2007-2010) and currently ASCO’s Government Relations Committee. He was involved with ASCO’s Tamoxifen and Raloxifene Working Group to develop guidelines for the use of Tamoxifen as a preventative agent. In 1998, he served as a member of ASCO’s Clinical Trials Subcommittee to survey and promote clinical research.


Donald S. Coffey, PhD
Professor of Urology and Oncology
The Johns Hopkins University School of Medicine

Donald S. Coffey, Ph.D. is a Professor of Urology, Oncology, and Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine. He is Director of the Research Laboratories of the Department of Urology. A prominent urological scientist, Dr. Coffey was appointed as the Catherine Iola and J. Smith Michael Distinguished Professor of Urology at the Johns Hopkins School of Medicine.

Dr. Coffey is also a member of the Principal Professional Staff at the Johns Hopkins University Applied Physics Laboratory. He received his Ph.D. in Biochemistry from The Johns Hopkins University School of Medicine in 1964. He is President of the American Association for Cancer Research for 1997-1998. He is Past-President of The Society for Basic Urologic Research and has served on several major editorial boards. For 19 years Dr. Coffey served as a member of the National Prostatic Cancer Program of the National Cancer Institute and served as National Chairman from 1984-1988. He has published over 200 research papers.

Dr. Coffey has received the Robert Ewards Award from the Tenovus Institute, The Fuller Award from the American Urological Association, and the First Society of International Urology- Yamanouchi Research Award. He is also the recipient of two Merit Awards from the National Institutes of Health.

Dr. Coffey died on November 9, 2017. He was 85 years old.

Robert L. Comis, MD

President and Chairman
Coalition of Cancer Cooperative Groups
Chair, Eastern Cooperative Oncology Group (ECOG)

Robert L. Comis, MD, President and Chairman of the Coalition of Cancer Cooperative Groups, is Group Chair of the Eastern Cooperative Oncology Group (ECOG), and Professor of Medicine and Director of the Drexel University Clinical Trials Research Center, Philadelphia, PA. A leader in international clinical trials research since 1977, Dr. Comis is a champion for patient access to cancer clinical trials, spearheading national efforts to raise awareness about the pivotal role of cancer clinical trials in cancer prevention, detection and treatment.

Dr. Comis is a member, Board of Directors, of C-Change and the National Coalition for Cancer Research. He has served on the editorial boards of the Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research. As elected Chairman of the National Cancer Institute-Cancer Cooperative Group Chairs, he was increasingly involved in raising the level of clinical trials in the cancer treatment area and in preparing the NCI-Cooperative Group System for the future. His previous board positions include the American Radium Society and the American Society of Clinical Oncology, where he served in a variety of other capacities including the Executive Committee and Chair of the Program, Nominating and Audit committees.

A graduate of Fordham University in New York City, Dr. Comis received his medical degree from SUNY Health Science Center School of Medicine in Syracuse, NY, where he also completed his medical internship and medical residency. He served as a Staff Associate at the National Cancer Institute, Bethesda, Maryland and completed a Medical Oncology Fellowship at The Sidney Farber Cancer Center at Harvard Medical School in Boston, MA. Dr. Comis is a Diplomat of the American Board of Internal Medicine, and a member of the American College of Physicians-American Society of Internal Medicine.

Dr. Comis passed away on Mary 20,2017. He was 71 years old.